Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
Wing Wai Yew, Won-Jung Koh
Korean J Intern Med. 2016;31(1):15-29.   Published online 2015 Dec 28     DOI: https://doi.org/10.3904/kjim.2016.31.1.15
Citations to this article as recorded by Crossref logo
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations
Rihwa Choi, Byeong-Ho Jeong, Won-Jung Koh, Soo-Youn Lee
Annals of Laboratory Medicine.2017; 37(2): 97.     CrossRef
Xpert® MTB/RIF: utilidad en el diagnóstico de la tuberculosis y de la resistencia a la rifampicina
Andrea Vergara Gómez, Julià González-Martín, Alberto L. García-Basteiro
Medicina Clínica.2017; 149(9): 399.     CrossRef
Xpert ® MTB/RIF: Usefulness for the diagnosis of tuberculosis and resistance to rifampicin
Andrea Vergara Gómez, Julià González-Martín, Alberto L. García-Basteiro
Medicina Clínica (English Edition).2017; 149(9): 399.     CrossRef
Clinical significance of smear positivity for acid-fast bacilli after ≥5 months of treatment in patients with drug-susceptible pulmonary tuberculosis
Hyung Koo Kang, Byeong-Ho Jeong, Hyun Lee, Hye Yun Park, Kyeongman Jeon, Hee Jae Huh, Chang-Seok Ki, Nam Yong Lee, Won-Jung Koh
Medicine.2016; 95(31): e4540.     CrossRef